HUGE is working out its new levels of Support and Resistance after a massive breakout.
FSD Pharma's front runner candidate, Lucid MS has recently begun its first round of clinical trials on a human subject.
Future projections of this security rely very heavily on the success of these clinical trials. If all goes well, the stock also has a massive potential for...
FSD Pharma and it's subsidiaries have progress in advancing their three drug candidates (PEA, Lycid Psych. & Lucid-MS) through clinical phases. After partnering with covar pharmaceuticals and Acquiring Lucid Psycheceuticals (subsidiary of FSD pharma Inc.), HUGE was able to recently purchase a new facility in Cobourg Ontario (CAD $17 million) which will be closing...
www.tradingview.com
FSD Pharma has been ahead of the bearish behaviors we are beginning to see in heavily weighted areas of the market. On top of that, the entire cannabis sector of the market has been experiencing this type of behavior quite some time way before these big sell offs in fear of inflation rates and interest. Now keep in mind once these sell offs...
In this for the long haul. This company is executing great things. Cannabis is the future of pharmaceuticals in a big way. When this things gets going it will rock.
Near Wedge bottom line.
Max volume profile is near 2.00
Entry 1.9
Stop 1.2
Target1 4.0
Target2 10.0
I am not a PRO trader. I trade option to test my trading plan with small cost.
The max Risk of each plan is less than 1% of my account.
If you like this idea, please use SIM/Demo account to try it.
FSD Pharma Inc (NASDAQ:HUGE) As you can see in the daily technical chart above, it looks like the stock is ready to continue its recent run higher. The bottom is rounding and technical indicators are beginning to turn positive again. Breakout watch over 2.09
I think it's fair to say at this stage FSD Pharma Inc (NASDAQ:HUGE) is way undervalued and that the selling has gone far beyond reason. I think a $1.80 break would be very bullish for this stock for a quick run to 2.40
FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such...
I am in at $2.35.
- Oversold, RSI @ 21
- $9.5 USD financing just closed at $3.10 CDN with insiders/institutions buying ahead of COVID-19 treatment Phase 2 trial results
- Will need to maintain $4+ stock price to stay listed on NASDAQ
- Gaps above at 3.33 & 5.56
- Signs of bottoming out
- $25M in cash; with Cannabis asset sale (~$20M), the cash position will exceed...
